Theranexus SA logo

ALTHX - Theranexus SA News Story

€3.45 0.3  8.0%

Last Trade - 21/01/22

Sector
Healthcare
Size
Micro Cap
Market Cap £13.2m
Enterprise Value £6.58m
Revenue £n/a
Position in Universe 737th / 851

BRIEF-Theranexus And BBDF Obtain ODD And RPDD From FDA For BBDF-101 For Batten Disease

Tue 11th August, 2020 5:27pm
Aug 11 (Reuters) - Theranexus SA  ALTHX.PA :
    * THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD)
AND
RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG
ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
    * PREPARING TO LAUNCH BBDF-101 PRECLINICAL TRIAL TO CONFIRM
PRECLINICAL SAFETY OF BBDF-101 OVER LONG EXPOSURE TIME, WITH AIM
OF SUPPLEMENTING DATA ALREADY AVAILABLE SO CLINICAL PROGRAM CAN
BE LAUNCHED IN 2021

Source text for Eikon:  ID:nACT64699 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.